Revisión de la Clase de Medicamentos: Moduladores inmunes dirigidos: Actualización del Informe Final 2

Categoría Síntesis amplia
LibroDrug Class Reviews
Año 2009
Cargando información sobre las referencias
Targeted immune modulators, commonly referred to as biological response modifiers or simply biologics, are a relatively new category of medications used in the treatment of certain types of immunologic and inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The US Food and Drug Administration approved the first of the biologics (infliximab) in 1998 and approved 9 additional agents since that time for treating various rheumatic conditions and plaque psoriasis: etanercept (1998), anakinra (2001), adalimumab (2002), alefacept (2003), efalizumab (2003), abatacept (2005), rituximab (2006), natalizumab (2008), and certolizumab pegol (2008). In this report, we review the comparative effectiveness, safety, and tolerability of targeted immune modulators.
Epistemonikos ID: 4a93e9c92158cf8c3c14a3cf38f261ae401bee4e
First added on: Jun 22, 2017